142 related articles for article (PubMed ID: 8336941)
21. p53 involvement in activation of the cytokeratin 8 gene in tumor cell lines.
Mukhopadhyay T; Roth JA
Anticancer Res; 1996; 16(1):105-12. PubMed ID: 8615594
[TBL] [Abstract][Full Text] [Related]
22. Modulation of gene expression by tumor-derived p53 mutants.
Scian MJ; Stagliano KE; Ellis MA; Hassan S; Bowman M; Miles MF; Deb SP; Deb S
Cancer Res; 2004 Oct; 64(20):7447-54. PubMed ID: 15492269
[TBL] [Abstract][Full Text] [Related]
23. Analysis of p53 transactivation through high-affinity binding sites.
Chumakov AM; Miller CW; Chen DL; Koeffler HP
Oncogene; 1993 Nov; 8(11):3005-11. PubMed ID: 8414502
[TBL] [Abstract][Full Text] [Related]
24. The proliferation-associated early response gene p22/PRG1 is a novel p53 target gene.
Schäfer H; Trauzold A; Sebens T; Deppert W; Fölsch UR; Schmidt WE
Oncogene; 1998 May; 16(19):2479-87. PubMed ID: 9627114
[TBL] [Abstract][Full Text] [Related]
25. Elevated expression of ribosomal protein genes L37, RPP-1, and S2 in the presence of mutant p53.
Loging WT; Reisman D
Cancer Epidemiol Biomarkers Prev; 1999 Nov; 8(11):1011-6. PubMed ID: 10566557
[TBL] [Abstract][Full Text] [Related]
26. Hetero-oligomerization does not compromise 'gain of function' of tumor-derived p53 mutants.
Deb D; Scian M; Roth KE; Li W; Keiger J; Chakraborti AS; Deb SP; Deb S
Oncogene; 2002 Jan; 21(2):176-89. PubMed ID: 11803461
[TBL] [Abstract][Full Text] [Related]
27. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
28. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.
Willis A; Jung EJ; Wakefield T; Chen X
Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206
[TBL] [Abstract][Full Text] [Related]
29. Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53.
Wang Q; Beck WT
Cancer Res; 1998 Dec; 58(24):5762-9. PubMed ID: 9865734
[TBL] [Abstract][Full Text] [Related]
30. A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function.
Kokontis JM; Wagner AJ; O'Leary M; Liao S; Hay N
Oncogene; 2001 Feb; 20(6):659-68. PubMed ID: 11313999
[TBL] [Abstract][Full Text] [Related]
31. Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s.
Kakudo Y; Shibata H; Otsuka K; Kato S; Ishioka C
Cancer Res; 2005 Mar; 65(6):2108-14. PubMed ID: 15781620
[TBL] [Abstract][Full Text] [Related]
32. The region 3' to the major transcriptional start site of the MDR1 downstream promoter mediates activation by a subset of mutant P53 proteins.
Strauss BE; Haas M
Biochem Biophys Res Commun; 1995 Dec; 217(1):333-40. PubMed ID: 8526930
[TBL] [Abstract][Full Text] [Related]
33. Tumour associated mutants of p53 can inhibit transcriptional activity of p53 without heterooligomerization.
Jõers A; Kristjuhan A; Kadaja L; Maimets T
Oncogene; 1998 Nov; 17(18):2351-8. PubMed ID: 9811466
[TBL] [Abstract][Full Text] [Related]
34. The neurogene BTG2TIS21/PC3 is transactivated by DeltaNp73alpha via p53 specifically in neuroblastoma cells.
Goldschneider D; Million K; Meiller A; Haddada H; Puisieux A; Bénard J; May E; Douc-Rasy S
J Cell Sci; 2005 Mar; 118(Pt 6):1245-53. PubMed ID: 15741235
[TBL] [Abstract][Full Text] [Related]
35. p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay.
Inga A; Monti P; Fronza G; Darden T; Resnick MA
Oncogene; 2001 Jan; 20(4):501-13. PubMed ID: 11313981
[TBL] [Abstract][Full Text] [Related]
36. Human smooth muscle alpha-actin gene is a transcriptional target of the p53 tumor suppressor protein.
Comer KA; Dennis PA; Armstrong L; Catino JJ; Kastan MB; Kumar CC
Oncogene; 1998 Mar; 16(10):1299-308. PubMed ID: 9546431
[TBL] [Abstract][Full Text] [Related]
37. Human p53 binds DNA as a protein homodimer but monomeric variants retain full transcription transactivation activity.
Tarunina M; Jenkins JR
Oncogene; 1993 Nov; 8(11):3165-73. PubMed ID: 8414520
[TBL] [Abstract][Full Text] [Related]
38. Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity.
Brazda V; Muller P; Brozkova K; Vojtesek B
Biochem Biophys Res Commun; 2006 Dec; 351(2):499-506. PubMed ID: 17070499
[TBL] [Abstract][Full Text] [Related]
39. Identification of the interferon regulatory factor 5 gene (IRF-5) as a direct target for p53.
Mori T; Anazawa Y; Iiizumi M; Fukuda S; Nakamura Y; Arakawa H
Oncogene; 2002 Apr; 21(18):2914-8. PubMed ID: 11973653
[TBL] [Abstract][Full Text] [Related]
40. Interaction of human polyomavirus BK with the tumor-suppressor protein p53.
Shivakumar CV; Das GC
Oncogene; 1996 Jul; 13(2):323-32. PubMed ID: 8710371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
